Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The New Zealand Intensive Medicines Monitoring Programme.

D M Coulter1

  • 1Centre for Adverse Reactions Monitoring, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand. david.coulter@stonebow.otago.ac.nz

Pharmacoepidemiology and Drug Safety
|April 10, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The New Zealand intensive medicines monitoring programme in pro-active safety surveillance.

Pharmacoepidemiology and drug safety·2008
Same author

Catastrophic intrauterine spinal cord injury caused by an arteriovenous malformation.

Journal of perinatology : official journal of the California Perinatal Association·2007
Same author

Privacy issues and the monitoring of sumatriptan in the New Zealand Intensive Medicines Monitoring Programme.

Pharmacoepidemiology and drug safety·2002
Same author

Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study.

BMJ (Clinical research ed.)·2001
Same author

Pharmacovigilance in Australia and New Zealand: towards 2000.

The Medical journal of Australia·1999
Same author

A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP).

British journal of clinical pharmacology·1999

The Intensive Medicines Monitoring Programme (IMMP) uses prescription follow-up and spontaneous reporting to track drug safety. This method enhances adverse event detection and risk factor identification in postmarketing surveillance.

Area of Science:

  • Pharmacovigilance
  • Drug Safety Monitoring
  • Clinical Epidemiology

Background:

  • The New Zealand Intensive Medicines Monitoring Programme (IMMP) has operated for 20 years.
  • Postmarketing surveillance is crucial for identifying drug-related adverse events.
  • Established monitoring programs require robust methodologies for data collection and analysis.

Purpose of the Study:

  • To describe the methodology and principles of the Intensive Medicines Monitoring Programme (IMMP).
  • To evaluate the advantages and challenges of the IMMP in postmarketing surveillance.
  • To assess the effectiveness of combined prescription follow-up and spontaneous reporting for adverse event detection.

Main Methods:

  • Establishing patient cohorts for drug monitoring.

Related Experiment Videos

  • Aggregating adverse events through prescription follow-up (PFU) and intensified spontaneous reporting.
  • Utilizing provisional causality assessment and analysis of non-reaction events (incidents) for signal detection and bias control.

    • Main Results:

    • Monitoring completed for 20 drugs with an average cohort size of 10,511 patients and a mean monitoring period of 55 months.
    • Duplicate prescriptions with PFU yielded significantly higher reporting rates compared to IMMP spontaneous reporting alone.
    • Questionnaires on therapy cessation effectively captured data on deaths and drug efficacy.

    Conclusions:

    • The IMMP methodology, combining PFU and intensified reporting, is effective for postmarketing drug safety surveillance.
    • The longer observation periods in smaller populations offer distinct advantages for detecting rare adverse events.
    • The IMMP provides valuable data for identifying drug risks and improving patient safety.